A strong two-chemo combination for soft-tissue sarcoma. Expect low blood counts (often with a booster) and strong nausea. Two ifosfamide effects to know: a temporary confusion/drowsiness that can occur around the infusion (tell staff right away), and bladder irritation — which is why you get mesna and extra fluids. Report any blood in the urine.
Doxorubicin + ifosfamide (with mesna to protect the bladder) every 3 weeks — an intensive sarcoma regimen, usually with a white-cell booster. Blood-count drops are nadir-based (~days 10-14). Two ifosfamide-specific things to watch: temporary CONFUSION (encephalopathy) during/after the infusion, and bladder irritation/bleeding (which mesna prevents). Doxorubicin's heart effect is CUMULATIVE.
Get help straight away — this is true on any regimen, on any day.
A temperature of 100.4°F (38°C) or higher during treatment can mean a
serious infection while your blood counts are low. Call your team or go to the ER — do not
wait it out.
Also urgent: trouble breathing or chest pain · swelling of the face, lips or throat ·
new confusion or fainting · shaking chills · not being able to keep fluids down.
This is standing guidance shown to everyone. Nothing on this page is based on anything
about you, and nobody is monitoring you.
Timed to the cycle
Day 1 is the day of your infusion. These are the effects a retrievable
document ties to a day range for this regimen — not a prediction about you.
Ifosfamide can temporarily affect the brain — causing confusion, drowsiness, hallucinations, or rarely seizures — usually during or within a day or two of the infusion. Tell staff at the first sign; it typically reverses after stopping the drug (sometimes with an antidote, methylene blue). It's more likely with low albumin, reduced kidney function, or prior cisplatin.
Call your team urgently: New confusion, hallucinations, extreme drowsiness, or a seizure — tell staff/seek care at once.
reported by about ~6-15% of people; severe in 4% · Timing from the manufacturer’s prescribing information · from Ifosfamide
Febrile neutropenia
Typically around days 8–21
Fever while infection-fighting white cells are low — common with this intensive combination, so a white-cell booster is usually given. It's a medical emergency needing immediate antibiotics.
Call your team urgently: Fever with feeling unwell — go to the ER and say you're on chemotherapy.
severe in 46% · Timing from the manufacturer’s prescribing information · from Ifosfamide, Doxorubicin
Anemia and low platelets
Typically around days 8–21
Drops in red cells (tiredness, breathlessness) and platelets (bruising, bleeding), lowest around days 10-14.
Call your team: New breathlessness, or bleeding that won't stop / black stools.
severe in 35 (anemia) / 33 (platelets)% · Timing from the manufacturer’s prescribing information · from Ifosfamide, Doxorubicin
Not tied to a cycle day
These build with the number of doses, or are measured from when treatment started, so a cycle day would be the wrong shape for them. Each keeps the timing its own source states.
Ifosfamide can irritate the bladder and cause bleeding — which is why you're given mesna and plenty of fluids to prevent it (this cuts the risk roughly in half or more). Report burning with urination or any blood in the urine.
Call your team: Blood in the urine, or trouble passing urine.
reported by about 21 (with mesna) vs 44 (without)% hematuria of people · from Ifosfamide
Nausea and vomiting
Sickness in the first 24 hours is the "acute" phase and usually peaks 2-3 hours in; anything from 24 to 120 hours is the "delayed" phase.
This is a strongly nausea-causing regimen, so you'll get robust anti-nausea prevention; it can be delayed over a few days.
Call your team: Can't keep fluids down for more than 12 hours.
reported by about ~33 (nausea)% of people; severe in 5-6% · Timing from a clinical guideline · from Doxorubicin, Ifosfamide
Heart-muscle weakening (cardiotoxicity)
cumulative; can appear months-years later
Doxorubicin can weaken the heart's pumping, with the risk rising as the total lifetime dose adds up. Your team tracks the cumulative dose and checks heart function; report breathlessness or swelling.
Call your team: New shortness of breath, swelling, or a rapid/irregular heartbeat.
reported by about ~3-5% CHF at ~400 mg/m² of people · from Doxorubicin
Hair loss
Hair loss is near-universal and grows back after treatment ends.
reported by about ~90% of people · from Doxorubicin
A window appears here only where a retrievable document ties it to a drug in
this regimen. Where nothing could be found, the window was removed rather than estimated —
so a missing time is an honest gap, not an oversight.
Oncura